MARKET

RUBY

RUBY

Rubius Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.01
+0.22
+3.24%
After Hours: 7.01 0 0.00% 16:04 12/04 EST
OPEN
6.82
PREV CLOSE
6.79
HIGH
7.06
LOW
6.65
VOLUME
166.95K
TURNOVER
--
52 WEEK HIGH
14.44
52 WEEK LOW
3.350
MARKET CAP
567.28M
P/E (TTM)
-3.2785
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.Contacts: Investors Elhan Webb, Head of Investor Relations elhan.webb@rubiustx.comMedia Marissa Hanify, Director, Corporate Communications Marissa.hanify@rubiustx.comDan Budwick, 1AB +1 (973) 271-6085 dan@1abmedia.com
GlobeNewswire · 4d ago
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST.
GlobeNewswire · 11/10 21:01
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST.A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.About Rubius TherapeuticsRubius Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® genetically engineers and cultures Red Cell Therapeutics to create selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of cancer and autoimmune diseases. Rubius’ initial product candidates are designed to activate and expand immune system function to fight cancer and modulate the immune system to induce tolerance for the treatment of autoimmune diseases. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.Contacts: Investors Lori Melançon, Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 lori.melancon@rubiustx.comMedia Marissa Hanify, Director, Corporate Communications Marissa.hanify@rubiustx.comDan Budwick, 1AB +1 (973) 271-6085 dan@1abmedia.com
GlobeNewswire · 11/10 21:01
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2  Solid Tumor Clinical TrialDosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational New Drug Application with U.S. Food and Drug Administration for RTX-321 for Human Papillomavirus 16-Positive Cancers with Frozen Drug SubstanceCAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported third quarter 2020 financial results and provided an overview of operational progress.“Rubius Therapeutics continues to demonstrate strong execution across our pipeline of Red Cell Therapeutics for the treatment of cancer. Our IND filing for RTX-321 included, for the first time, frozen drug substance as part of the manufacturing process, resulting in a truly off-the-shelf cellular therapy with a potential shelf life of up to several years,” said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. “As we continue to escalate the dose in the RTX-240 solid tumor trial, we are assessing the safety profile and biological effects of RTX-240 on innate and adaptive immune responses. We believe that by demonstrating that RTX-240 is working as intended to induce anti-tumor innate and adaptive immunity, we can unlock the potential of the RED PLATFORM® across our entire pipeline of cancer and autoimmune programs.”Third Quarter and Recent HighlightsRTX-240 Phase 1/2 Clinical Program for Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML) * Completed dosing of the fourth cohort in the Phase 1/2 solid tumor clinical trial * Assessing the safety profile and biological effects of RTX-240 on innate and adaptive immune responses by measuring biomarkers associated with activation and proliferation of NK and T cells in both peripheral blood and paired tumor biopsy samples across dose levels * Dosed the first patient with relapsed or refractory AML in second Phase 1 arm of ongoing RTX-240 clinical trial * Demonstrating robust momentum in manufacturing and producing clinical supply of RTX-240 for both arms in the Phase 1/2 clinical trial of RTX-240RTX-321 Artificial Antigen-Presenting Cell (aAPC) Development Program for Human Papillomavirus (HPV) 16-Positive Cancers * Filed an IND with U.S. FDA for RTX-321 for the treatment of HPV 16-positive cancers * For the first time, the IND filing includes frozen drug substance as part of the manufacturing process, resulting in a truly off-the-shelf cellular therapy with a potential shelf life of up to several years * Conducting manufacturing in support of planned GMP clinical supply needs for the RTX-321 clinical trial Leadership Team * Strengthened the leadership team by appointing Jose “Pepe” Carmona as chief financial officer * Pepe brings to Rubius extensive experience in global finance and operations, as well as a track record of financing clinical-stage and commercial biotech companiesPreclinical Data Presentations * This morning, Rubius presented preclinical data from its lead clinical oncology candidate, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting, demonstrating: * RTX-240 increased CD8 T cell and NK cell expansion and activation in vitro when compared to a combination of 4-1BB agonist antibody plus recombinant IL-15, which was directly correlated with the percentage of 4-1BBL and IL-15TP expressed on the cell surface * RTX-240 expanded CD56dim NK cells, a cell population with high cytotoxicity * RTX-240 promoted NK cell-killing of a myeloid leukemia cell line, K562, which was accompanied by increased NK cell degranulation and activation * A murine surrogate for RTX-240, mRBC-240, promoted significant expansion of CD8 T cells and NK cells in vivo in a murine model of colorectal cancer (CT26) * mRBC-240 demonstrated potent antitumor activity in a B16F10 melanoma model that was directly correlated with the expansion of terminally differentiated NK cells in the tumors * Presented preclinical data at the Federation of Clinical Immunology Societies Annual Meeting and the American Association of Cancer Research Tumor Immunology and Immunotherapy Conference, from its lead aAPC program, RTX-321, for the treatment of HPV 16-positive tumors demonstrating: * RTX-321 and its mouse surrogates demonstrated a dual mechanism of action in vivo * Functions as an aAPC to boost antigen-specific CD8+ T cell responses * Promotes antigenindependent stimulation of both innate and adaptive immune responses * Mouse surrogates of RTX-321 promote tumor control, memory formation and epitope spreading in tumor models in vivo * Treatment with the RTX-321 mouse surrogate results in minimal, reversible effects in vivo, likely due to biodistribution to the vasculature and spleen * RTX-321 functions as an aAPC to boost HPV 16 antigen-specific T cells in vitro * RTX-321 promotes HPV 16-independent adaptive and innate immune responses in vitroThird Quarter Financial ResultsNet loss for the third quarter of 2020 was $40.9 million or $0.51 per common share, compared to $47.0 million or $0.59 per common share in the third quarter of 2019.In the third quarter of 2020, Rubius invested $28.2 million in research and development (R&D) related to its novel RED PLATFORM® and towards expanding and advancing its product pipeline, as compared to $33.5 million in the third quarter of 2019. The year-over-year decrease was driven by a $7.5 million reduction in costs following the deprioritization of our rare disease pipeline in March 2020. The decrease in rare disease program expenses was offset by $9.6 million in incremental spend to advance our cancer programs, including costs associated with our Phase 1/2 clinical trial for RTX-240 for the treatment of solid tumors as well as costs associated with preclinical and IND-enabling activities for RTX-321. In addition, R&D expenses not allocated to programs decreased by $7.4 million driven primarily by reductions in non-program labor, laboratory supplies, research materials and contract research as pre-GMP manufacturing and discovery activities shifted to support the development of clinical candidates.G&A expenses were $12.0 million during the third quarter of 2020, as compared to $15.0 million for the third quarter of 2019. The lower costs were principally driven by a reduction in stock-based compensation expense.Nine Month Financial Results Net loss for the first nine months of 2020 was $127.2 million or $1.58 per common share, compared to $119.0 million or $1.52 per common share in the first nine months of 2019.In the nine months ended September 30, 2020, Rubius invested $90.5 million in R&D related to its novel RED PLATFORM® and towards expanding and advancing its product pipeline, as compared to $81.9 million in the first nine months of 2019. The year-over-year increase was driven by $28.3 million of incremental costs to advance our cancer programs, including costs incurred for our Phase 1/2 clinical trial for RTX-240 for the treatment of solid tumors as well as costs of preclinical and IND-enabling activities for RTX-321. The increase in cancer program costs was offset by a $12.8 million decrease in expenses related to our rare disease pipeline following the deprioritization of these programs in March 2020. Additionally, costs not allocated to programs decreased by $6.9 million driven primarily by a shift in manufacturing activities towards the technical development and production of clinical supply for our oncology programs and the shift in discovery activities from the development of clinical candidates towards work to support IND enabling activities.G&A expenses were $36.2 million during the first nine months of 2020, as compared to $42.3 million for the same period in 2019. The lower costs were principally driven by a reduction in stock-based compensation expense.Cash PositionAs of September 30, 2020, cash, cash equivalents and investments were $207.9 million as compared to $283.3 million as of December 31, 2019, providing Rubius with a cash runway into 2022. During 2020, the Company used $97.1 million of cash to fund operations and $4.5 million to fund capital expenditures, consisting mostly of payments for assets purchased in 2019. In addition, during 2020 the Company drew down the third and final tranche of $25.0 million pursuant to its $75.0 million loan agreement with Solar Capital.About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations with respect to the therapeutic potential of our pipeline of Red Cell Therapeutics, including RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors and RTX-321 for the treatment of HPV 16-positive cancers, our expectations regarding the timing, enrollment, data from and success of the future cohorts and phases of the clinical trial of RTX-240, our expectations regarding the biological effects of RTX-240 on innate and adaptive immunity, including activation and increased numbers of NK cells and T cells in higher-level dose cohorts in the clinical trial of RTX-240, any timelines related to the IND for RTX-321 and for any clinical trial of RTX-321, our expectations regarding our cash runway and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and subsequent filings with the SEC and risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. Rubius Therapeutics, Inc. Condensed Consolidated Statement of Operations (in thousands, except share and per share data) (unaudited) For the three months ended September 30,  For the nine months ended September 30,    2020  2019   2020  2019                 Revenue$  $   $  $   Operating expenses:              Research and development 28,209   33,530   90,491   81,919  General and administrative 11,976   14,952   36,241   42,254  Total operating expenses 40,185   48,482   126,732   124,173  Loss from operations (40,185)  (48,482)  (126,732)  (124,173) Other income (expense), net (667)  1,467   (460)  5,187  Net loss$(40,852) $(47,015) $(127,192) $(118,986) Net loss per share, basic and diluted$(0.51) $(0.59) $(1.58) $(1.52) Weighted average common shares outstanding, basic and diluted: 80,778,042   79,115,305   80,511,543   78,357,791  Rubius Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) September 30, December 31,  2020 2019 Cash, cash equivalents and investments$207,904 $283,287 Total assets 312,364  394,841 Total liabilities 139,249  120,628 Total stockholders’ equity 173,115  274,213 Contacts:Investors Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 lori.melancon@rubiustx.com Media  Marissa Hanify Director, Corporate Communications marissa.hanify@rubiustx.comDan Budwick 1AB +1 (973) 271-6085 dan@1abmedia.com
GlobeNewswire · 11/09 13:05
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2
GlobeNewswire · 11/09 13:05
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic(TM) Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer's Annual Meeting
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), today announced the presentation of new preclinical data supporting its lead clinical oncology program, RTX-240, at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting. The meeting is being held virtually from November 9-14, 2020.
GlobeNewswire · 11/09 13:00
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), today announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of RTX-240, an allogeneic cellular therapy product candidate that is being evaluated for the treatment of patients with relapsed/refractory or locally advanced solid tumors or relapsed/refractory AML. The ongoing clinical study of RTX-240 has two Phase 1 arms, one in all solid tumors and the other in relapsed/refractory AML. RTX-240 is engineered to stimulate innate and adaptive immunity by activating natural killer (NK) cells and T cells inside the patient's body to generate a potent anti-tumor immune response.
GlobeNewswire · 11/05 13:02
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of RTX-240, an allogeneic cellular therapy product candidate that is being evaluated for the treatment of patients with relapsed/refractory or locally advanced solid tumors or relapsed/refractory AML. The ongoing clinical study of RTX-240 has two Phase 1 arms, one in all solid tumors and the other in relapsed/refractory AML. RTX-240 is engineered to stimulate innate and adaptive immunity by activating natural killer (NK) cells and T cells inside the patient’s body to generate a potent anti-tumor immune response. “A number of studies show that NK cells can exhibit potent anti-tumor activity against AML, but tumor-associated mechanisms often suppress the proper function of NK cells leading to disease progression,” said Christina Coughlin, M.D., Ph.D., chief medical officer of Rubius Therapeutics. “When NK cells are restored to their full anti-tumor potential, their cytolytic activity predicts a better long-term outcome for patients with AML. RTX-240 is designed to replicate immune system function by activating and expanding a patient’s own NK and T cells in the body to generate an immune response against cancer.”RTX-240 is engineered to simultaneously express hundreds of thousands of copies of the costimulatory molecule 4-1BB ligand (4-1BBL) and the cytokine interleukin-15 (IL-15TP) to broadly stimulate both powerful arms of the immune system to generate anti-tumor immunity.“Despite advances in the management of AML, the overall outcome for patients with relapsed or refractory disease remains quite poor due to several factors, including lack of disease response to salvage therapy and the overall toxicity of the therapies,” said Alexander Spira, M.D., Ph.D., director of the Virginia Cancer Specialists Research Institute and the Phase I Trial Program. “RTX-240 potentially offers a novel way of treating relapsed/refractory AML by using the body’s own immune system to attack cancer. We look forward to working with Rubius Therapeutics on this differentiated approach to treating AML.”About Acute Myeloid Leukemia (AML) AML is a rare and aggressive cancer of the blood and bone marrow, and is the most common form of acute leukemia in adults. AML begins in the bone marrow and most often moves quickly into the blood or other areas of the body.Refractory AML occurs when patients have received treatment, typically two rounds of chemotherapy, but the disease does not go into remission. Some patients experience remission and then a return of the leukemia, which is referred to as relapsed AML. The overall outcome for patients with relapsed/refractory AML remains poor, with 5-year overall survival of approximately 10 percent. Limited therapeutic options currently exist for these patients.About the RTX-240 Clinical Trial Rubius Therapeutics is enrolling patients in a Phase 1/2 open label, multicenter, multidose, first-in-human dose-escalation and expansion study of RTX-240. The study contains two Phase 1 dose escalation arms: one in patients with relapsed/refractory or locally advanced solid tumors and another in patients with relapsed/refractory acute myeloid leukemia. These two Phase 1 arms will determine the safety and tolerability, pharmacokinetics, maximum tolerated dose and a recommended Phase 2 dose and dosing regimen of RTX-240 in patients with solid tumors as well as in patients with relapsed/refractory AML. The trial will also assess the pharmacodynamics of RTX-240 measured by changes in T and NK cell number and function relative to baseline and anti-tumor activity in both patient populations. The study will include an expansion phase in specified tumor types during the Phase 2 portion of the solid tumor arm. The extent to which the COVID-19 pandemic may impact Rubius’ ability to enroll patients in the trial will depend on future developments.About RTX-240 RTX-240 is an allogeneic cellular therapy product candidate that is being evaluated for the treatment of patients with relapsed/refractory or locally advanced solid tumors or relapsed/refractory acute myeloid leukemia. RTX-240 is engineered to simultaneously present hundreds of thousands of copies of the costimulatory molecule 4-1BBL and IL-15TP (trans-presentation of IL-15 on IL-15Rα) in their native forms and is designed to stimulate innate and adaptive immunity by activating NK cells and T cells inside the patient’s body to generate an anti-tumor immune response.About Rubius Therapeutics Rubius Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® genetically engineers and cultures Red Cell Therapeutics to create selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of cancer and autoimmune diseases. Rubius’ initial product candidates are designed to activate and expand immune system function to fight cancer and modulate the immune system to induce tolerance for the treatment of autoimmune diseases. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations regarding the therapeutic potential of our Red Cell Therapeutics, including RTX-240 for the treatment of solid tumors and acute myeloid leukemia, and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, expectations regarding the therapeutic potential of RTX-240 and our clinical study of RTX-240, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.Contacts: Investors Lori Melançon, Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 lori.melancon@rubiustx.comMedia Marissa Hanify, Director, Corporate Communications Marissa.hanify@rubiustx.comDan Budwick, 1AB +1 (973) 271-6085 dan@1abmedia.com
GlobeNewswire · 11/05 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RUBY. Analyze the recent business situations of Rubius Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RUBY stock price target is 10.67 with a high estimate of 28.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 76.85M
% Owned: 94.96%
Shares Outstanding: 80.92M
TypeInstitutionsShares
Increased
24
753.82K
New
24
-232.43K
Decreased
32
1.49M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
David Epstein
President/Chief Executive Officer/Director
Pablo Cagnoni
Chief Financial Officer/Chief Accounting Officer/Treasurer
Jose Carmona
Senior Vice President
Kris Elverum
Chief Scientific Officer
Laurence Turka
Other
Greg ..
Other
Christina Coughlin
Secretary
Maiken Keson-Brookes
Independent Director
Noubar Afeyan
Independent Director
Francis Cuss
Other
Greg Whitehead
Independent Director
Natalie Holles
Independent Director
Anne Prener
Independent Director
Michael Rosenblatt
Independent Director
Catherine Sohn
Independent Director
Jonathan Symonds
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RUBY
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Rubius Therapeutics Inc stock information, including NASDAQ:RUBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RUBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RUBY stock methods without spending real money on the virtual paper trading platform.